Earnings and Investment

Philips invests over $150 million in U.S. medtech manufacturing, expanding facilities and creating jobs to enhance AI-driven health care solutions.

The acquisitions give StatLab, a developer and manufacturer of medical diagnostic supplies and equipment, a direct foothold in France, Germany, Italy and the United Kingdom.

SetPoint Medical secures $140 million to launch innovative neuroimmune modulation therapy for rheumatoid arthritis, advancing treatment for autoimmune diseases.

Apreo Health pioneers emphysema treatment with innovative device trials, aiming to transform care for millions suffering from COPD.

Rowan University and NJEDA launch a Strategic Innovation Center to boost medical device investments and accelerate medtech innovation in South Jersey.

Edwards Lifesciences reports robust Q2 growth, raises 2025 guidance, driven by strong TAVR and TMTT sales, enhancing its market leadership.

New 154,000-square-foot Class A facility aims to address the growing demand for purpose-built life sciences manufacturing infrastructure.

DESKi secures $6 million in funding to expand AI-powered cardiac imaging tool

Medtronic announces a diabetes business spinoff to enhance focus on growth areas, aiming for improved financial performance and shareholder value.

GE HealthCare showcases strong Q1 earnings with revenue growth, strategic acquisitions, and new product launches, despite adjusting full-year guidance due to tariffs.

Cirtec Medical expands its Costa Rica operations, enhancing global manufacturing capabilities and meeting rising demand for high-quality medical devices.

RenovoCath is designed to deliver diagnostic and therapeutic agents directly to targeted tissues, offering a localized approach to treatment that can minimize systemic exposure.

$8 billion division grew 4.1% for the quarter

Trump's tariff announcements led to a stock market meltdown with trillions of dollars of losses from retirement accounts — at least on paper. What now? Here's what investors should consider.

The company also expects to submit its application for 510(k) clearance for its OneRF Trigeminal Nerve Ablation System in May, sooner than expected.

Swiss-based company’s plant will increase capacity to meet demand for autoinjectors

Under the terms, Boston Scientific will pay about $443 million upfront, plus up to $221 million if regulatory milestones occur.

Investment will support the expansion of its FDA-approved therapy designed to improve upper extremity function in chronic ischemic stroke survivors.